Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
insulin + sitagliptin + metformin
- Development stage
- Phase 4
- Lead developer
- Merck
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
This combination therapy for type 2 diabetes mellitus (T2DM) consists of three distinct anti-diabetic agents: insulin, sitagliptin, and metformin. **Insulin** is an exogenous hormone that facilitates peripheral glucose uptake and inhibits hepatic glucose production. **Sitagliptin** is a dipeptidyl peptidase 4 (DPP-4) inhibitor that increases the levels of active incretin hormones (GLP-1 and GIP), thereby stimulating insulin secretion and suppressing glucagon release in a glucose-dependent manner. **Metformin** is a biguanide that primarily reduces hepatic gluconeogenesis and improves insulin sensitivity. Research conducted by the Department of Endocrinology of the Affiliated Hospital of Jiangsu University has investigated this triple regimen's efficacy in stabilizing blood glucose fluctuations and preserving pancreatic beta-cell function in patients with T2DM who are inadequately controlled on standard therapies.
- Other names
- sitagliptin + metformin + insulininsulin, sitagliptin, and metformin combination
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)DPP-4 (Dipeptidyl Peptidase-IV)INSR (Insulin receptor)GPD2 (Glycerol-3-phosphate dehydrogenase 2)
Beyond the preview
Go deeper on insulin + sitagliptin + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on insulin + sitagliptin + metformin.